Ventripoint Diagnostics (TSXV: VPT) has seen its technology installed at the largest cardiac centre in Canada. The company announced this morning that its VMS+3.0 whole heart analysis system has seen its first install at the Peter Munk Cardiac Center in Toronto, Canada.
The Peter Munk Cardiac Centre resides at the University Hospital Network’s Toronto General Hospital. The addition of the device enables the Centre to be able to assess heart function in all four chambers of the heart via an echocardiogram, rather than that of an MRI. The technology enables the Hospital to manage and conduct future research in patients with right heart failure.
Commenting on the installation of the system, Executive Chairman of Ventripoint Dr George Adams stated, “just as it is PMCC’s mission to use the best equipment to optimize patient care, it has always been the Company’s mission to create “best-in-breed” equipment to assist clinicians and medical personnel in a myriad of clinical settings to accurately assess heart function. We feel incredibly privileged to have this world-leading hospital adopt our system.”
Sponsored · First Phosphate Corp.
The install marks the third install at a top-tier hospital in the last five weeks, while also being the fifth hospital in Canada to install the new VMS+3.0 system. Previously, the company installed a system at the Erasmus-Sophia University Medical Center in the Netherlands, one of the leading cardiac centres in Europe, as well as at the University of Texas MD Anderson Cancer Center, one of the worlds most respected cancer centres.
To date, a total of 10 VMS+3.0 systems have been delivered, with the company expecting to install units in additional leading cardiac centres before the end of the year.
Ventripoint Diagnostics last traded at $0.10 on the TSX Venture.
FULL DISCLOSURE: Ventripoint Diagnostics is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Ventripoint Diagnostics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
